Indian Journal of Private Psychiatry

Register      Login

VOLUME 13 , ISSUE 2 ( July-December, 2019 ) > List of Articles

ORIGINAL RESEARCH

Efficacy and Safety of Single Intravenous Ketamine Infusion as an Add-on to Escitalopram in Major Depression: A Randomized, Double-blind, Placebo-controlled Study

Shikha K Talati, Manu Sharma

Keywords : Ketamine, Randomized controlled trial,Depression

Citation Information : Talati SK, Sharma M. Efficacy and Safety of Single Intravenous Ketamine Infusion as an Add-on to Escitalopram in Major Depression: A Randomized, Double-blind, Placebo-controlled Study. Ind J Priv Psychiatry 2019; 13 (2):31-36.

DOI: 10.5005/jp-journals-10067-0041

License: CC BY-NC 4.0

Published Online: 00-12-2019

Copyright Statement:  Copyright © 2019; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Background: There is a paucity of studies exploring the role of ketamine as augmenting agent to conventional antidepressants. Materials and methods: Sixty patients with major depressive disorder (MDD) were randomized to 4 weeks’ double-blind treatment with escitalopram 10 mg/day + single-dose intravenous (IV) ketamine (0.5 mg/kg over 40 minutes) or escitalopram 10 mg/day + placebo (0.9% IV saline). Depressive symptoms were measured using the Montgomery–Asberg depression rating scale (MADRS), adverse effects were measured with the brief psychiatric rating scale (BPRS), young mania rating scale (YMRS), and clinician administered dissociative states scale (CADSS). Patients were assessed at baseline, 4, 24, and 48 hours and 7 days and 28 days. Response (50% MADRS score reduction) was the primary outcome. Results: The MADRS scores showed significant reduction in the group receiving ketamine as compared to group receiving placebo at 4, 24, and 48 hours, 1 week, and 28 days (p < 0.001). By 4 weeks, compared to escitalopram + placebo-treated patients, more of escitalopram + ketamine-treated patients responded (80% vs 20%) and remitted (21.67% vs 0%). Rapid response was evident at 4 hours in ketamine group as compared to placebo (36.67% vs 0%). Both CADSS and YMRS scores were significantly higher (p < 0.001) in the ketamine group as compared to the placebo group at 4 hours but not at 24 and 48 hours and 7 and 28 days. Conclusion: Single-dose IV ketamine as an add-on to 10 mg/day escitalopram is efficacious, resulting in more rapid and robust response over 4 weeks. Dissociative and mania-like symptoms emerging post-infusion are mild and transient, not warranting treatment discontinuation. Further research into the role of ketamine augmentation in MDD is required for its clinical applicability.


PDF Share
  1. World Health Organization. Depression and other common mental disorders: global health estimates. 2014.
  2. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR* D: implications for clinical practice. Am J Psychiatry 2006;163(1):28–40. DOI: 10.1176/appi.ajp.163.1.28.
  3. Papakostas GI, Thase ME, Fava M, et al. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry 2007;62(11):1217–1227. DOI: 10.1016/j.biopsych.2007.03.027.
  4. O'Connor RM, Pusceddu MM, Dinan TG, et al. Impact of early-life stress, on group III mGlu receptor levels in the rat hippocampus: Effects of ketamine, electroconvulsive shock therapy and fluoxetine treatment. Neuropharmacology 2013;66:236–241. DOI: 10.1016/j.neuropharm.2012.05.006.
  5. Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000;47(4):351–354. DOI: 10.1016/S0006-3223(99)00230-9.
  6. Newport DJ, Carpenter LL, McDonald WM, et al. APA council of research task force on novel biomarkers and treatments. Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression. Am J Psychiatry 2015;172(10):950–966. DOI: 10.1176/appi.ajp.2015.15040465.
  7. Andrade C. Ketamine for depression, 1: clinical summary of issues related to efficacy, adverse effects, and mechanism of action. J Clin Psychiatry 2017;78(4):e415–e419. DOI: 10.4088/JCP.17f11567.
  8. Hu YD, Xiang YT, Fang JX, et al. Single IV ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study. Psychol Med 2016;46(3):623–635. DOI: 10.1017/S0033291715002159.
  9. Zarate CA, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006;63(8):856–864. DOI: 10.1001/archpsyc.63.8.856.
  10. Cusin C, Ionescu DF, Pavone KJ, et al. Ketamine augmentation for outpatients with treatment-resistant depression: preliminary evidence for two-step intravenous dose escalation. Aust N Z J Psychiatry 2017;51(1):55–64. DOI: 10.1177/0004867416631828.
  11. Rybakowski JK, Permoda-Osip A, Bartkowska-Sniatkowska A. Ketamine augmentation rapidly improves depression scores in inpatients with treatment-resistant bipolar depression. Int J Psychiatry Clin Pract 2017;21(2):99–103. DOI: 10.1080/13651501.2017.1297834.
  12. Andrade C. Ketamine for depression, 2: diagnostic and contextual indications. J Clin Psychiatry 2017;78(5):e555–e558. DOI: 10.4088/JCP.17f11629.
  13. Diagnostic and statistical manual of mental disorders: DSM-IV-TR. New Delhi: Jaypee Brothers Medical Publishers; 2005.
  14. Sheehan D, Janavs J, Baker R, et al. MINI Plus. Mini International Neuropsychiatric Interview. University of SouthFlorida Institute for Research in Psychiatry Norwegian version. 2002;5.
  15. Zimmerman M, Posternak MA, Chelminski I. Derivation of a definition of remission on the Montgomery–Asberg depression rating scale corresponding to the definition of remission on the Hamilton rating scale for depression. J Psychiatr Res 2004;38(6):577–582. DOI: 10.1016/j.jpsychires.2004.03.007.
  16. Overall JE, Gorham DR. The brief psychiatric rating scale (BPRS): recent developments in ascertainment and scaling. Psychopharmacol Bull 1988;24(1):97–99.
  17. Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978;133(5):429–135. DOI: 10.1192/bjp.133.5.429.
  18. Bremner JD, Krystal JH, Putnam FW, et al. Measurement of dissociative states with the clinician-administered dissociative states scale (CADSS). J Trauma Stress 1998;11(1):125–136. DOI: 10.1023/A:1024465317902.
  19. Murrough JW, Perez AM, Pillemer S, et al. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry 2013;74(4):250–256. DOI: 10.1016/j.biopsych.2012.06.022.
  20. Kishimoto T, Chawla JM, Hagi K, et al. Single-dose infusion ketamine and non-ketamine N-methyl-D-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories. Psychol Med 2016;46(7):1459–1472. DOI: 10.1017/S0033291716000064.
  21. aan het Rot M, Collins KA, Murrough JW, et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry 2010;67(2):139–145. DOI: 10.1016/j.biopsych.2009.08.038.
  22. Liao Y, Tang J, Corlett PR, et al. Reduced dorsal prefrontal gray matter after chronic ketamine use. Biol Psychiatry 2011;69(1):42–48. DOI: 10.1016/j.biopsych.2010.08.030.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.